Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit

Belite Bio (NASDAQ: BLTE) will give an oral presentation on May 1, 2026 at the Retinal Therapeutics Innovation Summit in Denver covering topline Phase 3 DRAGON results for tinlarebant in Stargardt disease type 1.

Rhea-AI Summary

Belite Bio (NASDAQ: BLTE) will give an oral presentation on May 1, 2026 at the Retinal Therapeutics Innovation Summit in Denver covering topline Phase 3 DRAGON results for tinlarebant in Stargardt disease type 1.

According to the company, tinlarebant showed a 35.7% reduction in atrophic retinal lesion growth versus placebo and demonstrated a strong safety profile. Presentation details: May 1, 2026, 10:55-11:10 a.m. MDT, session "Small Molecules to the Rescue," presenter Nathan L. Mata, Ph.D.

Argus Apr 27 session

+1.12% close to close Open Argus

Details

News Market Reaction – BLTE

On Apr 27, the day this news came out, BLTE closed 1.12% above the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Market Context

This announcement centers on an upcoming scientific presentation that revisits previously disclosed ...

Analysis

This announcement centers on an upcoming scientific presentation that revisits previously disclosed Phase 3 DRAGON topline data, including a 35.7% reduction in atrophic retinal lesion growth versus placebo for tinlarebant in STGD1. In context of recent NDA rolling submission progress and prior conference activity, the key watchpoints remain regulatory milestones, any additional efficacy or safety details, and how these data are received by the retinal specialist community.

Key Figures

Lesion growth reduction: 35.7% Study duration: 2 years Presentation date: May 1, 2026 +1 more

Lesion growth reduction

35.7%

Reduction in atrophic retinal lesion growth vs placebo in Phase 3 DRAGON

Study duration

2 years

Phase 3 oral tinlarebant study in adolescent Stargardt disease patients

Presentation date

May 1, 2026

Retinal Therapeutics Innovation Summit oral presentation timing

Presentation time

10:55–11:10 a.m. MDT

Scheduled slot for oral tinlarebant Phase 3 DRAGON topline results

Historical Context

5 past events · Latest: Apr 23

5 events

1. Apr 23

   Investor conferences

   24h Move

   -1.8%

   Participation in four upcoming investor conferences with archived webcasts available.

2. Apr 21

   NDA rolling start

   24h Move

   +3.7%

   Initiation of rolling NDA submission to FDA for tinlarebant in STGD1.

3. Mar 31

   Annual report filed

   24h Move

   +6.9%

   Form 20-F with audited 2025 financials filed and made available to investors.

4. Mar 02

   Conference appearance

   24h Move

   -6.7%

   Announcement of participation in Leerink Global Healthcare Conference fireside chat.

5. Mar 02

   Earnings & trial data

   24h Move

   -6.7%

   Preliminary 2025 results plus positive Phase 3 DRAGON topline data and cash updates.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 3, stargardt disease type 1 (stgd1), atrophic retinal lesions

3 terms

phase 3 medical

"positive topline results from the Phase 3 DRAGON trial, which evaluated tinlarebant"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

stargardt disease type 1 (stgd1) medical

"tinlarebant for the treatment of Stargardt disease type 1 (STGD1). In the study,"

A genetic form of macular degeneration that typically causes progressive loss of central vision, often beginning in childhood or young adulthood. Think of it like the center of a camera sensor slowly failing, making sharp details and reading difficult while peripheral vision stays intact. Investors watch it because the condition creates a clear medical need and defined patient group, which drives demand for new therapies, clinical trial activity, and regulatory decisions that affect company value.

atrophic retinal lesions medical

"35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo"

Atrophic retinal lesions are patches where the light-sensitive layer at the back of the eye has thinned or broken down, often causing permanent loss of vision in the affected areas. For investors, they matter because the presence, progression, or improvement of these lesions drives demand for treatments, influences clinical trial outcomes and regulatory decisions, and therefore affects the market potential and valuation of companies working on therapies or diagnostics.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that the Company will give an oral presentation at the Retinal Therapeutics Innovation Summit being held on May 1, 2026, in Denver, Colorado.

The presentation will cover the previously disclosed positive topline results from the Phase 3 DRAGON trial, which evaluated tinlarebant for the treatment of Stargardt disease type 1 (STGD1). In the study, tinlarebant demonstrated a clinically meaningful 35.7% reduction in the growth rate of atrophic retinal lesions compared to placebo along with a strong safety profile. The presentation will be followed by a brief question and answer session.

Presentation Details
Session: Small Molecules to the Rescue
Title: Topline Results from a 2-year Phase 3 Study of Oral Tinlarebant in Adolescent Patients with Stargardt Disease
Presenter: Nathan L. Mata, Ph.D., Chief Scientific Officer, Belite Bio
Date and Time: May 1, 2026, 10:55-11:10 a.m. MDT
Location: Sheraton Denver Downtown Hotel, 1550 Court Place, Denver, CO

About Tinlarebant (a/k/a LBS-008)
Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in geographic atrophy (GA), or advanced dry age-related macular degeneration (AMD). Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Breakthrough Therapy Designation, Fast Track Designation, and Rare Pediatric Disease Designation in the U.S., Orphan Drug Designation in the U.S., Europe, Japan, and Sakigake Designation in Japan for the treatment of STGD1. In April 2026, Belite Bio initiated a rolling submission to the FDA for tinlarebant in the treatment of STGD1.

About Stargardt Disease (STGD1)
STGD1 is the most common inherited macular dystrophy in both adults and children. The disease is caused by mutations in a retina-specific gene (ABCA4), which results in progressive accumulation of bisretinoids leading to retinal cell death and progressive loss of central vision. The fluorescent properties of bisretinoids and the development of high-resolution retinal imaging systems have helped ophthalmologists identify and monitor disease progression. Currently, there are no approved treatments for STGD1.

About Belite Bio
Belite Bio is a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical need, such as Stargardt disease type 1 (STGD1) and geographic atrophy (GA) in advanced dry age-related macular degeneration (AMD), in addition to specific metabolic diseases. Belite Bio’s lead candidate, Tinlarebant, is an oral therapy intended to reduce the accumulation of bisretinoid toxins in the eye. The Company has completed a Phase 3 trial (DRAGON) in adolescent STGD1 subjects and is currently being evaluated in a Phase 2/3 trial (DRAGON II) in adolescent STGD1 subjects and a Phase 3 trial (PHOENIX) in subjects with GA. For more information, follow us on X, Instagram, LinkedIn, and Facebook, or visit us at www.belitebio.com.

Media and Investor Relations Contact:
Jennifer Wu
ir@belitebio.com

Julie Fallon
belite@argotpartners.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Belite Bio (BLTE) present at the Retinal Therapeutics Innovation Summit on May 1, 2026?

They will present topline Phase 3 DRAGON results for tinlarebant in Stargardt disease type 1. According to the company, the talk covers a 2-year oral study showing a 35.7% reduction in lesion growth and safety observations, followed by a brief Q&A session.

What were the key Phase 3 DRAGON results Belite Bio (BLTE) will discuss for tinlarebant?

The study showed a 35.7% reduction in atrophic retinal lesion growth versus placebo. According to the company, this result comes from a 2-year trial in adolescents with STGD1 and included a reported strong safety profile.

When and where will Belite Bio's (BLTE) oral presentation take place at the summit?

The presentation is scheduled for May 1, 2026, 10:55-11:10 a.m. MDT in Denver, Colorado. According to the company, it will be at the Sheraton Denver Downtown Hotel during the "Small Molecules to the Rescue" session.

Who is presenting Belite Bio's (BLTE) Phase 3 tinlarebant data at the Retinal Therapeutics Innovation Summit?

Nathan L. Mata, Ph.D., Chief Scientific Officer, will present the data. According to the company, Dr. Mata will summarize topline DRAGON trial results and participate in a brief question-and-answer session afterward.

What patient population was evaluated in the Phase 3 DRAGON trial Belite Bio (BLTE) will report on?

The trial evaluated adolescent patients with Stargardt disease type 1 (STGD1). According to the company, the DRAGON study was a 2-year Phase 3 trial assessing oral tinlarebant's effect on atrophic retinal lesion growth.

Does Belite Bio (BLTE) report any safety information for tinlarebant in the Phase 3 DRAGON topline results?

Yes; the company reports a strong safety profile alongside efficacy results. According to the company, safety findings accompanied the 35.7% reduction in lesion growth observed versus placebo in the DRAGON trial.